|
Geron is developing novel, first-in-class cancer therapeutics capable of meaningfully addressing the unmet medical needs of patients with cancer. We are advancing six Phase 2 clinical trials. Imetelstat, our lead telomerase inhibitor, is currently being evaluated in four Phase 2 clinical oncology studies for the following indications: non-small cell lung cancer, metastatic breast cancer, essential thrombocythemia and multiple myeloma. GRN1005, an LRP-directed peptide-drug conjugate, is being evaluated in two Phase 2 clinical trials, one for brain metastases arising from non-small cell lung cancer and the other for brain metastases arising from breast cancer. |
RSS Feeds | 
E-mail Alerts | 
Financial Tear Sheet